Whereas patients with multiple myeloma continue to relapse after autologous transplantation and are unlikely to be cured, the probability of progression is less after allogeneic transplantation and a proportion of patients may be cured. This is attributable to an immunologically mediated graft-versus-myeloma (GVM) effect which is akin to the well-known graft-versus-leukemia effect. The available clinical and experimental evidence strongly support the existence of GVM, but it is not known whether GVM is separable from graft-versus-host disease (GVHD) in practice. The best way to exploit GVM reactions is unclear, and the morbidity and mortality associated with GVHD undermine long-term survival. There is usually a time lag of a few weeks between immune intervention and disease response. There is a propensity for extramedullary disease recurrence in patients whose marrow disease is controlled with immunologic manipulation. Exploration of GVM outside conventional allogeneic transplantation or after autologous transplantation is necessary to increase the number of patients likely to benefit from this phenomenon and to make it safer. This article reviews the currently available literature on the subject.
to the well-characterized graft-versus-leukemia (GVL) effect 15, 16 operates after allogeneic transplantation for myeloma.
Clinical evidence for graft-versus-myeloma
In comparison with GVL, the number of published reports documenting successful or attempted exploitation of GVM is still relatively small. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] 
Graft-versus-myeloma as prophylaxis of relapse
Or et al 17 from the Hadassah University Hospital group from Jerusalem, in keeping with their pioneering work on donor T cell infusion to prevent and treat relapse after allogeneic transplantation, 33 were the first to attempt the induction of a graft-versus-tumor effect in a plasma cell disorder. 17 They allografted a patient with recurrent multiple extramedullary plasmacytomas and IgA paraproteinemia, who had failed conventional therapy, from her HLA-identical sibling with marrow depleted of T cells using the monoclonal antibody Campath-1. The transplant was followed by donor leukocyte infusions (DLI) in graded increments at weekly intervals to achieve GVM. No graft-versus-host disease (GVHD) was seen. The transplant and DLI resulted in complete eradication of all tumor masses and normalization of serum immunoglobulin levels. The patient was in complete remission (CR) 4 years after transplantation at the time of the original report, 17 and remains in continuous CR at 10 years (Slavin and Or, personal communication). Table 1 summarizes the published reports on the exploitation of GVM for treatment of relapse after allogeneic transplantation.
Graft-versus-myeloma as therapy of relapse
Pavord et al 18 administered interferon-␣ to a patient with IgA myeloma relapsing 3 months after T cell non-depleted allogeneic BMT from an HLA-identical sibling. Cutaneous GVHD developed after 2 weeks of interferon. The paraprotein level remained stable, and GVHD resolved after interferon was discontinued. No long-term follow-up is available on outcome and disease response.
Kolb et al, 19 on behalf of the European Group for Blood and Marrow Transplantation (EBMT), reported two patients who received DLI for relapsed myeloma; one with Table 1 Graft-versus-myeloma for treatment of relapse after allogeneic transplantation, and the relationship between GVHD and GVM Author/Ref.
No. of patients Intervention GVHD Response
Abraham 32 1 Stop cyclosporine Yes Yes Aschan 25 2 DLI, interleukin-2 1 1 (with GVHD) Bertz 28 1 Stop cyclosporine, DLI, interferon-␣ Yes Yes Collins 20 1 DLI, interferon-␣ Yes Yes Collins 27 4 DLI NS 2 Glass 30 1 DLI Yes No Kolb 19 2 DLI NS NS Lokhorst 22a 13 DLI 9 (acute) 8 (7 of 9 with and 1 of 4 without AGVHD; 6 7 (chronic) of 7 with and 0 of 5 without CGVHD) Orsini 29 4 CD8-depleted DLI 3 3 (all with GVHD) Pavord 18 1 20 reported a patient with primary refractory disease who did not respond to a T cell non-depleted allograft from an HLA-identical sibling. Four months after BMT, 1.63 × 10 8 donor mononuclear cells per kg were infused and interferon-␣ was started 4 weeks after DLI. The patient developed GVHD and achieved CR four months after DLI. The disease recurred 2 months later, but the tumor burden remained low, and the patient was reportedly alive with disease 2. years after DLI. 20 Verdonck et al 21 reported two patients with recurrent myeloma after T cell-depleted BMT. Both patients developed GVHD after DLI (у1 × 10 8 donor T cells per kg), achieved CR, and were alive in CR at 2 years and 8 months. 21 In a cooperative study from the Netherlands, Lokhorst et al 22 updated the initial report 21 of two patients and reported 11 more patients treated with DLI. All the patients had recurrent myeloma after T cell-depleted grafts from HLAidentical siblings. They received 29 courses of DLI containing 1 × 10 6 to 3.3 × 10 8 T cells per kg. Four patients achieved CR and four partial remission (PR). Ten patients were alive at the time of the report, two in CR.
The University of Arkansas group 23 reported a patient who experienced progressive disease after T cell-depleted BMT from an HLA-identical unrelated donor. An initial infusion of cryopreserved donor whole blood containing 10 6 nucleated cells per kg resulted in no apparent effect. Subsequently, an infusion of 1.2 × 10 6 T cells per kg in 100 ml fresh donor peripheral blood resulted in acute GVHD and CR. She eventually developed chronic GVHD, and died of a fungal infection while on corticosteroids. The disease recurred as the GVHD improved, and she had active disease at the time of death. 24 A subsequent report from Arkansas 24 described three more patients relapsing after T cell-depleted BMT from unrelated donors who received DLI. While all three responded, GVHD and death due to infectious complications or toxicity was the eventual outcome in all. Aschan et al 25 described two patients who were treated with a combination of DLI and interleukin-2 (IL-2) for relapse after T cell non-deleted BMT from HLA-identical siblings. The first patient responded partially to the first DLI without IL-2, but did not respond to the combination of DLI and IL-2. No GVHD was seen in this patient. The second patient developed GVHD after the combination of DLI and IL-2 and attained CR.
Forsyth et al 26 described a patient in whom allograft rejection and autologous erythropoietic recovery were accompanied by relapsed myeloma. Disease relapse was thought to be the result of the loss of GVM.
In a multicenter study of 140 patients with malignant diseases relapsing after allografting, Collins et al 27 reported CR in two of four evaluable myeloma patients receiving DLI from family donors. Details of the development of GVHD and long-term survival were not available.
Bertz et al 28 treated a patient who developed extramedullary relapse with multiple cutaneous plasmacytomas after T cell non-depleted allogeneic BMT. The patient developed acute and chronic GVHD after combined intervention with cessation of immunosuppression, DLI (6.2 × 10 7 donor T cells per kg), and interferon-␣. All the plasmacytomas disappeared, and the patient was reportedly in CR with extensive chronic GVHD. 28 The infusion of CD8-depleted donor leukocytes (CD4 ϩ cells) was reported to cause regression of relapsed disease in three of four patients who had undergone CD6-depleted BMT from HLA-identical siblings. 29 Response was associated with GVHD in all three patients.
Thirty of 97 patients allografted at the University of Arkanas relapsed following transplantation. 10 While 24 died of recurrent disease or complications of further therapy (including attempts to elicit GVM 24 ), six survive in CR or PR after various approaches to elicit GVM. 10 These approaches included, in varying combinations, withdrawal of immunosuppression, DLI, and administration of interferon-␣ or IL-2.
Glass et al 30 infused G-CSF-mobilized peripheral blood stem cells twice in a patient relapsing after BMT. No GVHD was seen after the first infusion. The second infusion resulted in grade II acute and limited chronic GVHD. However, no response was seen.
Zomas et al 31 reported a patient whose disease responded to a combination of chemotherapy and DLI. However, extramedullary relapse occurred. In the absence of any further therapy, the disease eventually relapsed in the marrow and the patient died.
Abraham et al 32 tapered cyclosporine rapidly in a patient who was allografted from an HLA-identical sibling and had detectable marrow plasmacytosis and paraproteinemia. CR was attained following cyclosporine withdrawal and development of grade IV GVHD. It is unclear whether this was definite GVM, or was partly attributable to the fact that low-grade lymphoid malignancies can sometimes take several weeks to clear after BMT. 34
Are graft-versus-host disease and graft-versusmyeloma separable?
While GVL reactions do appear to operate after allogeneic BMT ('primary' GVL) in the absence of clinically detectable GVHD, 15, 16 the relationship between GVHD and GVL is very strong after adoptive immunotherapy of relapsed disease ('salvage' GVL), especially in patients with acute leukemia. 27, 35, 36 Although the available data are limited, a small number of allografted myeloma patients do appear to survive long-term in remission without having developed GVHD. [12] [13] [14] This suggests that GVHD may not be essential for 'primary' GVM.
However, whether this holds true for patients who undergo immunotherapy for disease recurring after allogeneic transplantation ('salvage' GVM) is not known. Table 1 outlines the correlation between GVHD and GVM for the 29 patients for whom this information was available. Eighteen of 22 patients developing GVHD responded compared with two of seven not developing GVHD (P = 0.02; Fisher's exact test). This suggests that the relationship between GVHD and 'salvage' GVM is very strong.
In the patient originally reported by Tricot et al, 23, 24 the disease remained in remission while there was active GVHD. 37 As GVHD improved on combined immunosuppression with cyclosporine and prednisone, myeloma recurred. The patient eventually died of an opportunistic infection secondary to the immunosuppressive therapy with detectable paraprotein in the serum. 23, 37 The clinical course of this patient is similar to a patient with secondary acute myeloid leukemia whose disease recurred coincidentally with improvement in GVHD twice, 38 and who eventually died of relapse. 36 The Dana-Farber group studied the T cell receptor repertoire in four patients with relapsed myeloma who received CD4 ϩ lymphocyte infusions from HLA-identical sibling donors. 29 Clonal T cell populations emerged after DLI in each of the three responding patients. Some clones appeared within 3 months after DLI and coincided with disease response, whereas other clones appeared later and coincided with the development of GVHD. Sensitive PCR study of CDR III region sequences and a semi-quantitative hybridization assay for the junctional region of each clone showed that the early clones (temporally associated with GVM) were detectable by PCR before DLI and expanded at least 10-fold in the first 3 months after DLI. In contrast, the late clones (temporally associated with GVHD) were not detectable either prior to DLI or in the first 3 months after DLI. These findings suggest that DLI may mediate antitumor activity through an indirect effect on pre-existing T cell populations, whereas the induction of GVHD may be mediated through new T cell populations developing after DLI. 29 These data suggest that GVHD and GVM may be potentially separable.
The University of Arkansas approach to exploit GVM without GVHD consists of the administration of donor T cells transduced with the Herpes simplex virus thymidine kinase (TK) gene after T cell-depleted BMT. 39, 40 Transduction of the viral TK suicide gene permits specific killing of marked T cells with ganciclovir. Laboratory data show that adequate numbers of TK-transduced lymphocytes can be selected efficiently with у90% purity, the selected cells remain functional, 24 h of exposure to ganciclovir at clinically achievable concentration kills у90% of the selected cells, and ganciclovir can kill TK-transduced cells in vivo. 39 Patients with persistent or recurrent disease after T celldepleted allogeneic BMT receive TK-transduced cells followed electively by ganciclovir 3 weeks later. 39 In the absence of response or GVHD, a second DLI is administered six weeks after the first. Ganciclovir is then administered only if there is GVHD. Dose escalation of TK-marked cells has been planned from 1 × 10 6 T cells per kg to 5, 10, 20 and 50 × 10 6 T cells per kg in cohorts of three patients each. None of the three patients receiving both infusions at the first dose level developed GVHD, and one patient experienced a reduction of monoclonal protein and marrow plasmacytosis. TK-marked cells were detectable 6 weeks after the second infusion in all patients in the absence of ganciclovir therapy. 40 The 3 week interval to ganciclovir administration was based on the phenomenon seen in one patient, 23 where it was felt that the entire antitumor effect was completed in the first two weeks after DLI, prior to the onset of GVHD. However, this assumption, in light of the Dana-Farber data, 29 may not be correct. Also, as most other reports show, the time interval to response after DLI is generally several weeks (vide infra). A better way to separate GVHD and GVM may be to monitor T cell clones after DLI, and withhold ganciclovir as long as no new clones appear to emerge. Ganciclovir could be administered when there is clinical evidence of GVHD or appearance of new T cell clones.
A practical problem with the TK transduction approach is that the gene-marked cells are also susceptible to acyclovir and related drugs (famciclovir and valaciclovir). Thus antiviral prophylaxis and therapy (particularly for cytomegalovirus 41 ) in these patients becomes exceedingly difficult with the relatively toxic intravenous foscarnet 42 as the only choice.
It is difficult to achieve a balance between active GVHD (morbidity but ongoing GVM) on the one hand, and immunosuppressive therapy of GVHD (infectious complications as well as compromised GVM) on the other. One potential way of doing this is to treat only patients whose GVHD is progressive, and to avoid immunosuppressive therapy when GVHD is limited. When GVHD is treated, the use of single agents other than corticosteroids (cyclosporine or tacrolimus) may be considered if possible to avoid severe immunosuppression. In patients with GVHD, especially those requiring intensive immunosuppression including corticosteroids, careful attention should be paid to broad-spectrum antimicrobial prophylaxis 43 to avoid opportunistic infections.
Time to disease response after immune intervention
Low-grade lymphoid malignancies take time to respond after high-dose therapy and autologous or allogeneic transplantation. 44, 45 Similarly, time to response after induction of GVL for relapsed disease may also be prolonged especially with diseases such as chronic myeloid 27 or lymphocytic 34 leukemia. Table 2 shows that it generally takes some weeks for response to become obvious after DLI, and a few months to attain CR. The apparently short time to response after the second DLI in the patient described by Tricot et al 23 may have been due to the inherent HLA disparity in an unrelated donor-recipient pair (more powerful GVM) or due to a rapid expansion of pre-existing clones triggered by the first of the two DLIs. 29
The effect of the cell dose on response
Variable cell doses have been used to elicit GVM. Although the Dutch group 22 tried escalating cell doses, they found that the infusion of Ͼ1 × 10 8 T cells/kg was associated with the best response rates (four of six compared with four of 21 infusions containing р1 × 10 8 T cells/kg). The two patients who did not respond to high T cell doses did not develop GVHD.
Since GVHD appears to be at least a surrogate marker for subsequent GVM (if not the actual phenomenon responsible for GVM), the correct dose of T cells would appear to be the one which causes some GVHD. Therefore, it is probably reasonable to escalate the T cell dose with each infusion until some GVHD is seen.
The four unrelated donor transplant recipients treated at the University of Arkansas 24 received much smaller cell doses per kg body weight: 1.2 × 10 6 T cells, 1.2 × 10 6 T cells, 1.1 × 10 6 T cells, and 6 × 10 6 nucleated cells, respect- 20 HLA-matched sibling 1 NS 4 months Tricot 23 HLA-matched unrelated 1 2 weeks 7 weeks Lokhorst 22 HLA-matched siblings 13 Median NS 6 weeks (range, 4-10 weeks) a This patient had, sequentially, withdrawal of immunosuppression, donor cell infusion, and interferon-␣. The time shown represents time from withdrawal of immunosuppression. Donor cells were administered 3 weeks after stopping immunosuppression and interferon was started 10 days after donor cells. NS = not specified.
ively. However, response (and GVHD) was seen in all. This indicates that a much smaller number of T cells may be required after an unrelated BMT to cause GVHD and GVM because of the inherent histoincompatibility. Higher cell doses may be required if the histocompatibility between unrelated donors and recipients is particularly good: an unrelated BMT recipient we are treating presently did not develop GVHD or GVM despite having received 1 × 10 6 TK-marked T cells per kg twice, 10 × 10 6 CD4 ϩ cells once, 0.8 × 10 6 T cells per kg during myelosuppression after chemotherapy, 23 × 10 6 T cells per kg in the steady state, Ͼ1 × 10 8 T cells per kg after 100 mg melphalan, and interferon-␣, interferon-, and IL-2 injections. The donor and the recipient share two ancestral haplotypes 46 resulting in very close HLA identity.
As a starting point, 0.5-1 × 10 8 T cells per kg may be reasonable from HLA-identical siblings and 0.5-1 × 10 6 T cells per kg from HLA-mismatched or unrelated donors. It is not known if the dose of T cells needed to elicit GVM is higher in patients relapsing after T cell non-depleted grafts.
Extramedullary disease recurrence after immunotherapy
Isolated extramedullary relapse of leukemia is not common after allogeneic BMT, 47 although this unusual phenomenon is a noticeable problem in acute leukemia patients treated with immunotherapy for relapse after allografting. 36 It is not uncommon to see isolated extramedullary recurrence following immunotherapy of myeloma relapsing after allografting (unpublished data). 31 These extramedullary lesions are not just bony lesions but soft tissue masses anywhere in the body. The management of this problem is unsatisfactory. Isolated lesions may be amenable to radiation or intra-arterial chemotherapy. However, systemic disease control needs to be maintained through ongoing GVM to prevent marrow recurrence. 37 CD13 (aminopeptidase N), a cell surface enzyme linked to tumor cell invasion, 48 is associated with the retinoic acid syndrome in acute promyelocytic leukemia. 49 Malignant plasma cells infiltrating the stomach were found to coexpress CD13 in a patient with plasma cell leukemia. 50 CD13 expression by malignant cells may result in a propensity to develop extramedullary deposits in patients who have been treated with immunotherapy for disease recurrence posttransplant; this association has not been studied.
Prophylactic immunotherapy
The ideal way to exploit GVM would be to identify patients at high risk of disease progression on the basis of disease biology or other factors (such as poor immunologic reconstitution 51 or lack of GVHD), and augment immune responses in them.
With T cell-depleted grafts, this could be accomplished with graded T lymphocyte repletion, 52 or the administration of interferon-␣, 53 interferon-␥, or interleukin-2. 54 With T cell non-depleted grafts, this could be accomplished by abbreviating the duration of immunosuppression or the administration of cytokines. The risk of getting severe GVHD due to immune manipulations in the relatively early stages after transplantation 34 must be carefully weighed against potential benefits.
The idiotype of the myeloma paraprotein can be used as a unique tumor-specific antigen. Immunization of the donor with the recipient's idiotype protein prior to the harvest can augment T cell-mediated specific immunity against the idiotype. 55 There is evidence in a murine B cell lymphoma model that reconstitution with marrow from idiotypeimmune donors can confer protection against subsequent lethal tumor challenge. 56 If the anti-idiotype response is similarly protective in myeloma, immunization of the donor before harvest and/or before collecting cells for DLI could selectively boost GVM. Infusion of dendritic cells loaded with the myeloma protein after BMT is another potential way of enhancing GVM effects of allogeneic transplantation by stimulating T cell-mediated specific immunity.
Graft-versus-myeloma independent of conventional allogeneic transplantation
The high toxic death rates after conventional allogeneic transplantation undermine long-term disease-free survival. 10, 11 Attempts have therefore been made to exploit allogeneic GVM outside the setting of conventional allogeneic BMT to avoid the usual morbidity and mortality. [57] [58] [59] [60] These approaches have included conditioning with nonmyeloablative but adequately immunosuppressive regimens to achieve secure alloengraftment. 57, 58 This is followed by DLI in gradual increments to induce graft-versus-tumor reactions and to convert the mixed chimerism (if present) to full donor-type chimerism. Early results suggest that this is immunologically feasible but longer follow-up is required to show anti-tumor activity and sustained diseasefree survival. We have started a pilot study recently comprising 100 mg/m 2 melphalan as non-myeloablative conditioning followed by four infusions of G-CSF-mobilized donor stem cells on days 0, 21, 42 and 114; the first three under the cover of cyclosporine and the last after cyclosporine is discontinued.
Attempts have been made to exploit 'hit-and-run' 61,62 graft-versus-tumor effects by infusing haploidentical donor cells in conjunction with a conventional autograft. 60 This has been tried in a small number of patients who were being transplanted for the second or third 59 time. Fatal toxicity including GVHD was a serious problem in patients receiv-ing this therapy with their third autografts. Although survival of donor cells for several weeks was seen in the few patients receiving this therapy with their second autografts, all patients eventually relapsed and the efficacy of this treatment could not be judged.
Infusion of mononuclear cells from HLA-identical sibling donors has been tried without any preceding conditioning therapy. 60 While almost all patients had donor cells detectable immediately after infusion, one-fourth had donor cells detectable more than 4 weeks after infusions and all of these developed GVHD. There appeared to be transient antitumor responses in two patients (including one with myeloma) during GVHD. These data are too limited to evaluate the efficacy of this approach.
Autologus graft-versus-myeloma
Apart from the toxicity seen with allogeneic transplantation, the limited availability of suitably matched donors makes it accessible only to a minority of patients who are relatively young and fit. Because of its safety, exploitation of graft-versus-tumor reactions in the autologous setting is potentially very attractive. 63 Although a number of studies have shown that a short course of cyclosporine given after autografting can cause a clinical and histologic syndrome resembling GVHD in animal models and human beings, 63 antitumor activity has been seen only in a rat model against a plasmacytoma cell line. 64 Giralt et al 65 administered cyclosporine for 28 days after autografting to 14 myeloma patients after conditioning with thiotepa, busulfan and cyclophosphamide. One patient developed clinical skin GVHD which responded to corticosteroids. Six patients developed histologic evidence of GVHD without clinical signs. The clinical outcome of these patients was as would be expected with a standard autograft. Thus, while this report shows that induction of autologous GVHD is feasible and reasonably well-tolerated in myeloma patients, it is not possible to assess the antitumor effect. Byrne et al 66 described apparent response of myeloma in a patient who developed spontaneous 'autologous' GVHD following an autograft. However, it is possible that the administration of corticosteroids as therapy of GVHD contributed to the response.
Vaccination with the myeloma idiotype protein 67 and infusion of idiotype-pulsed dendritic cells once a minimal residual disease state has been attained after autotransplantation are other potential ways of exploiting immune reactions against myeloma. While immune responses to the idiotype are seen, there is no evidence to show that these responses are protective since there are no data yet to show disappearance of residual disease with the onset of immune response, and relapses have already been seen in patients with anti-idiotype immune responses.
Questions
Because of the limited availability of data, many clinically relevant questions about GVM remain unanswered. These include the separability of GVHD and GVM, the optimum starting cell dose for DLI, interval between DLIs, administration of chemotherapy prior to DLI, the use of cytokines such as interferon-␣ or IL-2, management of extramedullary relapse, induction of GVM independent of conventional allogeneic transplantation, and induction of autologous GVM.
Approach to a patient with myeloma relapsing after an allograft
The best way to treat a relapsed patient would be in the context of clinical trials evaluating one or more of the questions outlined above. In the absence of a well-designed study, a reasonable approach would depend upon the patient's general condition, nature of the graft, current immunosuppression, time from transplant, and tumor burden. Figure 1 shows a potential algorithm based upon our approach to leukemia 35 and myeloma 37 relapsing after allogeneic transplantation.
Conclusions
GVM effects operating after allogeneic BMT are responsible for curing a proportion of patients with myeloma. The best way to exploit GVM is unclear, and morbidity of accompanying GVHD is a major problem. There is usually a lag of a few weeks between immune intervention and disease response. There is a propensity for extramedullary disease recurrence in patients whose marrow disease is controlled with immunologic manipulations. Exploration of GVM independent of conventional allogeneic transplantation or after autologous transplantation is necessary to increase the number of patients likely to benefit from this phenomenon and to make it safer.
